Cipla's 'core' growth offsets weak show in US, Covid portfolio
![](https://img.etimg.com/thumb/msid-87293997,width-1070,height-580,imgsize-81724,overlay-etmarkets/photo.jpg)
Contributing over 40% to total revenues, domestic market sales grew 16% on a high base of Covid-led drug sales. Sustained growth in the company's core therapies such as respiratory and urology compensated for the normalising contribution of the Covid portfolio.
via Economictimes
Post a Comment